Cargando…

Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes

PURPOSE: Magnetoliposomes (MLs) have shown great potential as magnetic resonance imaging contrast agents and as delivery vehicles for cancer therapy. Targeting the MLs towards the tumor cells or neovascularization could ensure delivery of drugs at the tumor site. In this study, we evaluated the pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia Ribeiro, Rita Sofia, Belderbos, Sarah, Danhier, Pierre, Gallo, Juan, Manshian, Bella B, Gallez, Bernard, Bañobre, Manuel, de Cuyper, Marcel, Soenen, Stefaan J, Gsell, Willy, Himmelreich, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681073/
https://www.ncbi.nlm.nih.gov/pubmed/31534330
http://dx.doi.org/10.2147/IJN.S214041
_version_ 1783441648163749888
author Garcia Ribeiro, Rita Sofia
Belderbos, Sarah
Danhier, Pierre
Gallo, Juan
Manshian, Bella B
Gallez, Bernard
Bañobre, Manuel
de Cuyper, Marcel
Soenen, Stefaan J
Gsell, Willy
Himmelreich, Uwe
author_facet Garcia Ribeiro, Rita Sofia
Belderbos, Sarah
Danhier, Pierre
Gallo, Juan
Manshian, Bella B
Gallez, Bernard
Bañobre, Manuel
de Cuyper, Marcel
Soenen, Stefaan J
Gsell, Willy
Himmelreich, Uwe
author_sort Garcia Ribeiro, Rita Sofia
collection PubMed
description PURPOSE: Magnetoliposomes (MLs) have shown great potential as magnetic resonance imaging contrast agents and as delivery vehicles for cancer therapy. Targeting the MLs towards the tumor cells or neovascularization could ensure delivery of drugs at the tumor site. In this study, we evaluated the potential of MLs targeting the αvβ3 integrin overexpressed on tumor neovascularization and different tumor cell types, including glioma and ovarian cancer. METHODS: MLs functionalized with a Texas Red fluorophore (anionic MLs), and with the fluorophore and the cyclic Arginine-Glycine-Aspartate (cRGD; cRGD-MLs) targeting the αvβ3 integrin, were produced in-house. Swiss nude mice were subcutaneously injected with 10(7) human ovarian cancer SKOV-3 cells. Tumors were allowed to grow for 3 weeks before injection of anionic or cRGD-MLs. Biodistribution of MLs was followed up with a 7T preclinical magnetic resonance imaging (MRI) scanner and fluorescence imaging (FLI) right after injection, 2h, 4h, 24h and 48h post injection. Ex vivo intratumoral ML uptake was confirmed using FLI, electron paramagnetic resonance spectroscopy (EPR) and histology at different time points post injection. RESULTS: In vivo, we visualized a higher uptake of cRGD-MLs in SKOV-3 xenografts compared to control, anionic MLs with both MRI and FLI. Highest ML uptake was seen after 4h using MRI, but only after 24h using FLI indicating the lower sensitivity of this technique. Furthermore, ex vivo EPR and FLI confirmed the highest tumoral ML uptake at 4 h. Last, a Perl’s stain supported the presence of our iron-based particles in SKOV-3 xenografts. CONCLUSION: Uptake of cRGD-MLs can be visualized using both MRI and FLI, even though the latter was less sensitive due to lower depth penetration. Furthermore, our results indicate that cRGD-MLs can be used to target SKOV-3 xenograft in Swiss nude mice. Therefore, the further development of this particles into theranostics would be of interest.
format Online
Article
Text
id pubmed-6681073
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66810732019-09-18 Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes Garcia Ribeiro, Rita Sofia Belderbos, Sarah Danhier, Pierre Gallo, Juan Manshian, Bella B Gallez, Bernard Bañobre, Manuel de Cuyper, Marcel Soenen, Stefaan J Gsell, Willy Himmelreich, Uwe Int J Nanomedicine Original Research PURPOSE: Magnetoliposomes (MLs) have shown great potential as magnetic resonance imaging contrast agents and as delivery vehicles for cancer therapy. Targeting the MLs towards the tumor cells or neovascularization could ensure delivery of drugs at the tumor site. In this study, we evaluated the potential of MLs targeting the αvβ3 integrin overexpressed on tumor neovascularization and different tumor cell types, including glioma and ovarian cancer. METHODS: MLs functionalized with a Texas Red fluorophore (anionic MLs), and with the fluorophore and the cyclic Arginine-Glycine-Aspartate (cRGD; cRGD-MLs) targeting the αvβ3 integrin, were produced in-house. Swiss nude mice were subcutaneously injected with 10(7) human ovarian cancer SKOV-3 cells. Tumors were allowed to grow for 3 weeks before injection of anionic or cRGD-MLs. Biodistribution of MLs was followed up with a 7T preclinical magnetic resonance imaging (MRI) scanner and fluorescence imaging (FLI) right after injection, 2h, 4h, 24h and 48h post injection. Ex vivo intratumoral ML uptake was confirmed using FLI, electron paramagnetic resonance spectroscopy (EPR) and histology at different time points post injection. RESULTS: In vivo, we visualized a higher uptake of cRGD-MLs in SKOV-3 xenografts compared to control, anionic MLs with both MRI and FLI. Highest ML uptake was seen after 4h using MRI, but only after 24h using FLI indicating the lower sensitivity of this technique. Furthermore, ex vivo EPR and FLI confirmed the highest tumoral ML uptake at 4 h. Last, a Perl’s stain supported the presence of our iron-based particles in SKOV-3 xenografts. CONCLUSION: Uptake of cRGD-MLs can be visualized using both MRI and FLI, even though the latter was less sensitive due to lower depth penetration. Furthermore, our results indicate that cRGD-MLs can be used to target SKOV-3 xenograft in Swiss nude mice. Therefore, the further development of this particles into theranostics would be of interest. Dove 2019-07-29 /pmc/articles/PMC6681073/ /pubmed/31534330 http://dx.doi.org/10.2147/IJN.S214041 Text en © 2019 Garcia Ribeiro et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Garcia Ribeiro, Rita Sofia
Belderbos, Sarah
Danhier, Pierre
Gallo, Juan
Manshian, Bella B
Gallez, Bernard
Bañobre, Manuel
de Cuyper, Marcel
Soenen, Stefaan J
Gsell, Willy
Himmelreich, Uwe
Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title_full Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title_fullStr Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title_full_unstemmed Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title_short Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
title_sort targeting tumor cells and neovascularization using rgd-functionalized magnetoliposomes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681073/
https://www.ncbi.nlm.nih.gov/pubmed/31534330
http://dx.doi.org/10.2147/IJN.S214041
work_keys_str_mv AT garciaribeiroritasofia targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
AT belderbossarah targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
AT danhierpierre targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
AT gallojuan targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
AT manshianbellab targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
AT gallezbernard targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
AT banobremanuel targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
AT decuypermarcel targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
AT soenenstefaanj targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
AT gsellwilly targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes
AT himmelreichuwe targetingtumorcellsandneovascularizationusingrgdfunctionalizedmagnetoliposomes